Chargement en cours...
Aberrant signalling by protein kinase CK2 in imatinib‐resistant chronic myeloid leukaemia cells: Biochemical evidence and therapeutic perspectives
Chronic myeloid leukaemia (CML) is driven by the fusion protein Bcr‐Abl, a constitutively active tyrosine kinase playing a crucial role in initiation and maintenance of CML phenotype. Despite the great efficacy of the Bcr‐Abl‐specific inhibitor imatinib, resistance to this drug is recognized as a ma...
Enregistré dans:
| Publié dans: | Mol Oncol |
|---|---|
| Auteurs principaux: | , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
John Wiley and Sons Inc.
2013
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5528438/ https://ncbi.nlm.nih.gov/pubmed/24012109 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2013.08.006 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|